Octozi Raises $3 Million in Seed Funding
Octozi, a New York-based company specializing in automating clinical data workflows through AI, has successfully raised $3 million in a seed funding round. The funding, announced on July 7, 2026, was led by Surface Ventures, with additional participation from Remarkable Ventures and Debiopharm.
Company Overview
Octozi focuses on optimizing clinical data management by using AI agents to streamline tasks such as data cleaning, review, reconciliation, reporting, and clinical operations. This approach aims to reduce the time and complexity associated with traditional clinical data workflows, offering a more efficient solution for sponsors.
Investment Details
The seed funding round was spearheaded by Surface Ventures, a firm known for its investments in technology-driven companies. Remarkable Ventures and Debiopharm also participated in this round, demonstrating a strong interest in Octozi's innovative approach to clinical data management.
Leadership Perspective
Matt Purri, Chief Technology Officer and Co-Founder of Octozi, plays a pivotal role in the company's technological advancements. Although direct quotes from Purri are not available, his leadership is crucial in driving the company's mission to enhance clinical data processes through AI.
Use of Funds
While specific plans for the newly acquired funds have not been detailed, it is expected that Octozi will channel this investment into further developing its AI capabilities, expanding its team, and enhancing its product offerings.
Conclusion
With the successful completion of its seed funding round, Octozi is well-positioned to continue its growth in the clinical data management sector. The involvement of prominent investors like Surface Ventures underscores confidence in Octozi's potential to transform the industry through innovative AI solutions.